ALK-Abelló A/S (ALK-B) - Total Liabilities

Latest as of December 2025: Dkr2.73 Billion DKK ≈ $426.66 Million USD

Based on the latest financial reports, ALK-Abelló A/S (ALK-B) has total liabilities worth Dkr2.73 Billion DKK (≈ $426.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ALK-Abelló A/S - Total Liabilities Trend (2005–2025)

This chart illustrates how ALK-Abelló A/S's total liabilities have evolved over time, based on quarterly financial data. See ALK-Abelló A/S current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

ALK-Abelló A/S Competitors by Total Liabilities

The table below lists competitors of ALK-Abelló A/S ranked by their total liabilities.

Company Country Total Liabilities
Manhattan Associates Inc
NASDAQ:MANH
USA $535.36 Million
Vicinity Centres
AU:VCX
Australia AU$5.19 Billion
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
China CN¥11.39 Billion
Frontline Ltd
NYSE:FRO
USA $3.24 Billion
SICC Co. Ltd.
SHG:688234
China CN¥2.32 Billion
Viper Energy Ut
NASDAQ:VNOM
USA $1.68 Billion
Primo Brands Corporation
NYSE:PRMB
USA $7.63 Billion
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
Germany €288.99 Billion

Liability Composition Analysis (2005–2025)

This chart breaks down ALK-Abelló A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of ALK-Abelló A/S.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.38 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ALK-Abelló A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ALK-Abelló A/S (2005–2025)

The table below shows the annual total liabilities of ALK-Abelló A/S from 2005 to 2025.

Year Total Liabilities Change
2025-12-31 Dkr2.73 Billion
≈ $426.66 Million
-5.08%
2024-12-31 Dkr2.87 Billion
≈ $449.50 Million
+26.06%
2023-12-31 Dkr2.28 Billion
≈ $356.57 Million
-1.77%
2022-12-31 Dkr2.32 Billion
≈ $362.98 Million
-1.28%
2021-12-31 Dkr2.35 Billion
≈ $367.67 Million
-2.49%
2020-12-31 Dkr2.41 Billion
≈ $377.06 Million
+3.92%
2019-12-31 Dkr2.32 Billion
≈ $362.82 Million
+37.54%
2018-12-31 Dkr1.69 Billion
≈ $263.79 Million
+1.08%
2017-12-31 Dkr1.67 Billion
≈ $260.97 Million
-13.31%
2016-12-31 Dkr1.92 Billion
≈ $301.02 Million
+23.73%
2015-12-31 Dkr1.55 Billion
≈ $243.29 Million
+46.01%
2014-12-31 Dkr1.06 Billion
≈ $166.63 Million
+4.51%
2013-12-31 Dkr1.02 Billion
≈ $159.43 Million
+2.10%
2012-12-31 Dkr998.00 Million
≈ $156.14 Million
-15.92%
2011-12-31 Dkr1.19 Billion
≈ $185.71 Million
+46.18%
2010-12-31 Dkr812.00 Million
≈ $127.04 Million
+12.00%
2009-12-31 Dkr725.00 Million
≈ $113.43 Million
+7.25%
2008-12-31 Dkr676.00 Million
≈ $105.77 Million
-4.65%
2007-12-31 Dkr709.00 Million
≈ $110.93 Million
+2.01%
2006-12-31 Dkr695.00 Million
≈ $108.74 Million
-1.70%
2005-12-31 Dkr707.00 Million
≈ $110.62 Million
--

About ALK-Abelló A/S

CO:ALK-B Denmark Biotechnology
Market Cap
$8.49 Billion
Dkr54.27 Billion DKK
Market Cap Rank
#2554 Global
#13 in Denmark
Share Price
Dkr269.60
Change (1 day)
-0.30%
52-Week Range
Dkr177.10 - Dkr270.40
All Time High
Dkr270.40
About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more